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Background. A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT,
MenAfriVac) was developed to control epidemic group A meningitis in Africa. Documentation of the safety spec-
iﬁcations of the PsA-TT vaccine was warranted, with sufﬁcient exposure to detect potential rare vaccine-related
adverse reactions.
Methods. This phase 3, double-blind, randomized, active controlled clinical study was designed to evaluate the
safety—primarily vaccine-related serious adverse events (SAEs)—up to 3 months after administration of a single
dose of the PsA-TT vaccine to subjects aged 1–29 years in Mali. Safety outcomes were also compared to those fol-
lowing a single dose of a licensed meningococcal ACWY polysaccharide vaccine (PsACWY).
Results. No vaccine-related SAEs occurred during the 3 months of follow-up of 4004 subjects vaccinated with a
single dose of PsA-TT. When compared to PsACWY (1996 subjects), tenderness at the injection site appeared to be
more frequent in the PsA-TT group. However, rates of local induration, systemic reactions, adverse events (AEs), and
SAEs were similar in both groups, and unsolicited AEs and SAEs were all unrelated to the study vaccines.
Conclusions. The study conﬁrmed on a large scale the excellent safety proﬁle of a single dose of PsA-TT when
administered to its entire target population of 1–29 years of age.
Clinical Trials Registration. PACTR ATMR201003000191317.
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Controlling group A meningococcal disease is a public
health priority. Every 10–12 years, the region of sub-
Saharan Africa extending from Senegal to Ethiopia,
known as the meningitis belt, experiences major epi-
demics of meningococcal meningitis [1]. These
epidemics have been most commonly caused by
group A Neisseria meningitidis.
Since 2001, the Meningitis Vaccine Project, a part-
nership between the World Health Organization
(WHO) and PATH, funded by the Bill & Melinda
Gates Foundation, has aimed to eliminate group A me-
ningococcal disease through the development of an
affordable group A meningococcal conjugate vaccine
that induces immunologic memory and a long-lasting
immune response [2].
This effort led to the licensure, followed by WHO
prequaliﬁcation, of PsA-TT (MenAfriVac, Serum Insti-
tute of India, Ltd) in June 2010 after 4 clinical studies
(phase 1, 2, and 2/3) that included a total of 1915 sub-
jects, of whom 1126 from age 1 to 34 years had received
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at least 1 dose of PsA-TT, and which demonstrated its safety
and superior immune response compared with the group A–
containing polysaccharide vaccine [3–8]. Two additional clini-
cal studies (phase 3), a lot consistency study in India and a large
safety study in Africa, were ongoing at the time of prequaliﬁca-
tion and submitted to regulatory authorities as part of the early
postlicensure requirements.
Here we present the results of the large phase 3 safety trial
conducted in 2010 in Bamako, Mali, to collect additional data
on the safety proﬁle of PsA-TT in a randomized controlled set-
ting [9–12], while allowing sufﬁcient exposure to detect poten-
tial rare vaccine-related adverse reactions, where “rare” is
conventionally deﬁned as ≤1 per 1000 vaccinees [13].
METHODS
Study Design and Oversight
This phase 3, double-blind, randomized, active controlled clin-
ical study (PsA-TT-006) was designed to evaluate the safety of a
single intramuscular injection of the study vaccine up to 3
months after vaccination, in healthy residents of the study
area; it was intended to increase the safety database and to fur-
ther document the safety speciﬁcations of PsA-TT. The study
was performed in children, adolescents, and adults aged 1–29
years, recruited at the Center for Vaccine Development in Ba-
mako, Mali. Six thousand eligible subjects were randomized in a
2:1 ratio to receive either the study vaccine (PsA-TT, MenAfri-
Vac, Serum Institute of India; group 1, n = 4004) or the refer-
ence vaccine (PsACWY, Mencevax ACWY, GlaxoSmithKline;
group 2, n = 1996). The sample size was stratiﬁed into 3 age
groups (children 1–10 years, adolescents 11–17 years, and
adults 18–29 years of age) to ensure a balanced safety informa-
tion across the target population of 1–29 years of age [14]. Each
participant made 1 vaccination visit and 3 follow-up visits (at 4
days, 28 days, and 84 days after vaccination). Only the staff
members at the study sites who were directly responsible for
preparing the vaccines were aware of group assignments; the
subjects and their families, other site staff members, investiga-
tors, and sponsors were blinded and unaware of group assign-
ments throughout the study period.
The main criteria for exclusion were a history of allergic dis-
ease or known hypersensitivity to any component of the 2 study
vaccines and/or following administration of vaccines included
in the local program of immunization; administration of any
other vaccine within 30 days prior to administration of study
vaccines or planned vaccination during the ﬁrst 28 days after
the study vaccination; or pregnancy or lactation (prelicensing
vaccine trials did at that time not usually include pregnant
and lactating women). A negative pregnancy test was required
before vaccination for all women of childbearing potential (ie,
postmenarcheal or married women). The study was conducted
in accordance with the study protocol and was designed and
conducted in accordance with the Good Clinical Practice guide-
lines established by the International Conference on Harmoni-
sation and with the Declaration of Helsinki. The participating
community approved the study, and written informed consent
was obtained before enrollment from all subjects between 18
and 29 years of age and from all parents or guardians of subjects
<18 years of age. In addition, written informed assent was ob-
tained from subjects 10–17 years of age as appropriate within
the participating community. The study was approved by the
PATH and WHO ethics committees, as well as by the ethics
committee and the national regulatory authority in Mali.
Vaccines
A reconstituted dose of PsA-TT (0.5 mL) contained 10 µg of
group A polysaccharide conjugated to 10–33 µg of tetanus
toxoid, 2.85 mg of mannitol, 0.72 mg of sucrose, 0.3 mg alumin-
ium(III) ion as aluminum phosphate as adjuvant, TRIS buffer,
0.01% thiomersal (preservative), and 0.9% sodium chloride,
and water for injection.
A reconstituted dose of reference vaccine, PsACWY (0.5 mL),
contained 50 µg of puriﬁed polysaccharide from each of the N.
meningitidis groups A, C, Y, and W, sucrose, trometamol, so-
dium chloride, phenol, and sterile water for injection.
The vaccines were injected intramuscularly, in the right thigh
for children <2 years of age, and in the right deltoid for children
aged ≥2 years, adolescents, and adults.
Safety Evaluation
Subjects were observed for 30 minutes after vaccination to record
and treat immediate reactions. Subjects were monitored for local
and systemic postimmunization reactions during daily home vis-
its by nurses and doctors using diaries for 4 days, unsolicited ad-
verse events (AEs) were assessed for 1 month, and serious adverse
events (SAEs) were assessed throughout the course of the study
for 3 months. Subjects (or their parents or guardians) were asked
about tenderness and induration at the injection site; fever, vom-
iting, and diarrhea (for all subjects); lethargy, irritability, and loss
of appetite (for subjects between 1 and 10 years of age); and
headache, fatigue, myalgia, and arthralgia (for subjects >10
years of age). Solicited reactions within 4 days after vaccination
were presumed to be vaccine related. Assessment of causality
in the case of unsolicited AEs was performed by the study inves-
tigators based on clinical judgment. An independent data and
safety monitoring board was established.
Statistical Analysis
The primary objective of this study was to evaluate the safety up
to 3 months (84 days) after a single dose of PsA-TT, in terms of
vaccine-related SAEs. The primary analysis on the primary end-
point was descriptive.
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The safety of a single dose of PsA-TT was compared to that of
1 dose of PsACWY, in terms of local and systemic reactions, AEs,
and SAEs. Differences between the 2 vaccine groups were tested
using a Cochran–Mantel–Haenszel test adjusting for age group
for percentage of subjects with at least 1 postimmunization reac-
tion (local or systemic), percentage of subjects reporting the pres-
ence of each reactogenicity parameter (however, for lethargy,
irritability, and loss of appetite in those aged 1–10 years, the com-
parison was made by Fisher exact test at a 2-sided signiﬁcance
level of α = .05), and percentage of subjects with at least 1 AE
or SAE. Because lethargy, irritability, and loss of appetite were
only collected in the age group of 1–10 years, Fisher exact test
was used to compare the 2 vaccine groups for percentage of sub-
jects with at least 1 of these 3 postimmunization reactions.
All safety analyses were carried out on the intention-to-treat
dataset. Data were analyzed with SAS software, version 9.1.3.
A 2-sided signiﬁcance level of .05 was used for testing. Calcu-
lations of the sample size, required to assess the primary
objective with sufﬁcient power, were based on the probability
of observing a rare AE as derived by a Poisson approximation
[15]. When the incidence rate (R0) of a particular AE is suf-
ﬁciently low and a sample size is sufﬁciently large, the proba-
bility of observing an AE can be approximated by that of a
Poisson distribution with parameter λ = nR0. If no vaccine-
related SAE was observed in the estimated 4000 participants
who were supposed to receive a single dose of the PsA-TT
vaccine, one can conclude with a 95% conﬁdence that the
incidence of the vaccine-related SAE for PsA-TT vaccine is
<1 in 1333 vaccinated individuals.
RESULTS
Study Population
Of the 6077 randomized subjects, 6000 were vaccinated between
22 February and 9 October 2010: 4004 in the PsA-TT group
and 1996 in the PsACWY group (Figure 1). All vaccinated
Figure 1. Study population. Abbreviations: PsACWY, group A, C, W, Y meningococcal polysaccharide vaccine; PsA-TT, group A meningococcal polysac-
charide-tetanus toxoid conjugate vaccine.
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subjects were included in the analyses. The duration of study
participation for each subject was 3 months: all subjects com-
pleted the initial vaccine period of 28 days, and all but 4 subjects
completed the study with an additional 56 days of follow-up
(Figure 1). Demographic and clinical characteristics of the
subjects are summarized in Table 1.
Safety
Primary Endpoint
No vaccine-related SAE occurred during the 3 months of follow-
up. Therefore, no further analyses were required on the primary
criterion.
Secondary Endpoints
Postimmunization reactions and AEs are shown in Table 2. No
allergic or anaphylactic reaction occurred immediately after im-
munization. Rates of systemic reactions during the ﬁrst 4 days
after immunization, rates of AEs during the ﬁrst 28 days after
immunization, and SAEs within 84 days after immunization
were similar among vaccine groups.
However, the rate of local reactions was 3 times as high in the
PsA-TT group as in the PsACWY group (13.1% vs 4.3%;
P < .0001). All but 2 mild indurations were injection-site tender-
ness, with a between-group rate difference increasing with age of
the subjects. Intensity of tenderness was rated 1 (mild pain to
touch) for all subjects in the PsACWY group and for most of
the subjects in the PsA-TT group. In the PsA-TT group, tender-
ness intensity rated 2 (signiﬁcant pain to touch) was reported as
follows: 0 children, 7 adolescents (3.7% of 189 adolescents who
reported tenderness), and 21 adults (8.0% of 264 adults who re-
ported tenderness). Only 1 adult reported a tenderness of inten-
sity 3 (signiﬁcant pain on moving the limb).
Rates of systemic reactions were low (2.9% in PsA-TT vs 3.2%
in PsACWY) and increased with age of the subjects: 1.4% vs
1.2% in children; 2.0% vs 2.4% in adolescents, and 4.5% vs
5.0% in adults in the PsA-TT vs PsACWY groups, respectively.
Headache, fatigue, myalgia, and arthralgia (solicited only
among adolescents and adults) were the most frequently report-
ed systemic postimmunization reactions, with 3.0% vs 3.4% of
the subjects in the PsA-TT vs PsACWY group, respectively, re-
porting at least 1 of these 4 reactions. Headache was the most
frequently reported reaction: 2.3% in PsA-TT vs 2.8% in PsAC-
WY, twice as frequent in adults than in adolescent subjects. Fa-
tigue was reported more frequently in the PsACWY group
(1.1% vs 0.5% in the PsA-TT group; P = .0160). Overall, local
and systemic postimmunization reactions were mild, transient,
and resolved without sequelae.
A total of 10.1% subjects in the PsA-TT group and 11.6%
of subjects in the PsACWY group reported at least 1 unsolic-
ited AE. Commonly reported AEs were infections and infes-
tations according to system organ class (SOC), mainly
malaria, upper respiratory tract infections, schistosomiasis,
and rhinitis. Adverse events were transient and resolved
without sequelae, and no vaccine-related unsolicited AEs
were recorded.
Within 3 months after vaccination, 48 subjects—34 subjects
(0.8%) in the PsA-TT group and 14 (0.7%) in the PsACWY
group—reported experiencing 50 serious AEs, all of which were
vaccine unrelated (Table 3). One adolescent had vascular disorder
according to SOC (severe malignant hypertension) and died 57
days after vaccination with PsA-TT; the event was unrelated to
the study vaccine. Twenty-nine subjects (0.7%) in the PsA-TT
group and 14 (0.7%) in the PsACWY group reported a total of
45 SAEs that were infections and infestations according to SOC,
mainly malaria (34 cases). The remaining 4 SAEs were 2 cases of
injury, poisoning, and procedural complications (multiple injuries,
forearm fracture), and 1 case each of gastrointestinal disorders (ap-
pendicitis) and surgical andmedical procedures (induced abortion)
and were reported in 4 subjects in the PsA-TT group. Most of the
cases of SAEs were severe (43/50) or moderate (7/50), but all,
Table 1. Age, Sex, Height, and Weight of Study Subjects
Age Group, y
Vaccine
Group No.
Median Age, Years
(Min–Max) Female, No. (%)
Median Height, cm
(Min–Max)
Median Weight, kg
(Min–Max)
1–10 PsA-TT 799 8 (1–10) 396 (49.6) 125.5 (70.0–159.2) 22.0 (7.0–59.0)
PsACWY 401 7 (1–10) 187 (46.6) 124.0 (70.0–172.0) 22.0 (7.0–55.0)
11–17 PsA-TT 1600 14 (11–17) 737 (46.1) 156.5 (122.0–193.0)* 47.0 (20.0–94.5)**
PsACWY 800 14 (11–17) 368 (46.0) 155.0 (128.0–183.4)* 45.0 (23.0–90.0)**
18–29 PsA-TT 1605 21 (18–29) 542 (33.8) 167.2 (145.1–195.0) 61.0 (36.0–129.0)
PsACWY 795 21 (18–29) 252 (31.7) 167.3 (137.0–199.0) 61.0 (36.5–103.0)
Total PsA-TT 4004 16 (1–29) 1675 (41.8) 159.0 (70.0–195.0) 51.0 (7.0–129.0)
PsACWY 1996 16 (1–29) 807 (40.4) 157.6 (70.0–199.0) 50.0 (7.0–103.0)
Abbreviations: PsACWY, group A, C, W, Ymeningococcal polysaccharide vaccine; PsA-TT, group Ameningococcal polysaccharide-tetanus toxoid conjugate vaccine.
* P = .0093 for the comparison of PsACWY vs PsA-TT in the age group 11–17 years using analysis of variance (ANOVA).
** P = .0204 for the comparison of PsACWY vs PsA-TT in the age group 11–17 years (ANOVA).
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except for the fatal case, recovered without sequelae. The overall
comparison adjusted for age groups showed no statistically signiﬁ-
cant difference in the percentage of subjects with at least 1 SAE be-
tween the 2 vaccine groups with respect to SAEs after vaccination.
There was no difference when comparing the rates within each fol-
low-up period of before or after the ﬁrst 28 days postimmunization.
For detailed data on solicited local and systemic reactions,
AEs, and SAEs, see the Supplementary Tables.
Table 2. Overall Vaccine Safety Proﬁle
Local Reaction Systemic Reactiona Adverse Event
Serious Adverse
Event
Within 4 d
Postimmunization
Within 4 d
Postimmunization
Within 28 d
Postimmunization
Within 84 d
Postimmunization
Age Group, y Vaccine Group No. No. % (95% CI) No. % (95% CI) No. % 95% CI) No. % (95% CI)
1–10 PsA-TT 799 72 9.0 (7.1–11.2) 11 1.4 (.7–2.4) 100 12.5 (10.3–15.0) 7 0.9 (.4–1.8)
PsACWY 401 16 4.0 (2.3–6.4) 5 1.2 (.4–2.9) 61 15.2 (11.8–19.1) 3 0.7 (.2–2.2)
11–17 PsA-TT 1600 189 11.8 (10.3–13.5) 32 2.0 (1.4–2.8) 119 7.4 (6.2–8.8) 11 0.7 (.3–1.2)
PsACWY 800 35 4.4 (3.1–6.0) 19 2.4 (1.4–3.7) 79 9.9 (7.9–12.2) 5 0.6 (.2–1.5)
18–29 PsA-TT 1605 265 16.5 (14.7–18.4) 73 4.5 (3.6–5.7) 187 11.7 (10.1–13.3) 16 1.0 (.6–1.6)
PsACWY 795 35 4.4 (3.1–6.1) 40 5.0 (3.6–6.8) 92 11.6 (9.4–14.0) 6 0.8 (.3–1.6)
Total PsA-TT 4004 526 13.1b (12.1–14.2) 116 2.9 (2.4–3.5) 406 10.1 (9.2–11.1) 34 0.8 (.6–1.2)
PsACWY 1996 86 4.3b (3.5–5.3) 64 3.2 (2.5–4.1) 232 11.6 (10.2–13.1) 14 0.7 (.4–1.2)
Abbreviations: CI, confidence interval; PsACWY, group A, C, W, Y meningococcal polysaccharide vaccine; PsA-TT, group A meningococcal polysaccharide–tetanus
toxoid conjugate vaccine.
a Subjects reporting at least 1 of fever, vomiting, and diarrhea: age group 1–10 years, 1.0% of subjects (95% CI, .4%–2.0%; n/N = 8/799) in the PsA-TT group and
0.7% of subjects (95% CI, .2%–2.2%; n/N = 3/401) in the PsACWY group; 11–17 years, 0.3% of subjects (95% CI, .1%–.7%; n/N = 5/1600) in PsA-TT and 0.4% of
subjects (95% CI, .1%–1.1%; n/N = 3/800) in PsACWY; and 18–29 years, 0.6% of subjects (95% CI, .3%–1.1%; n/N = 9/1605) in PsA-TT and 0.6% of subjects (95%
CI, .2%–1.5%; n/N = 5/795) in PsACWY. Subjects reporting at least 1 of lethargy, irritability, and loss of appetite: age group 1–10 years, 0.8% of subjects (95% CI,
.3%–1.6%; n/N = 6/799) in the PsA-TT group and 0.5% of subjects (95% CI, .1%–1.8%; n/N = 2/401) in the PsACWY group. Subjects reporting at least 1 of
headache, fatigue, myalgia, and arthralgia: age group 11–17 years, 1.8% of subjects (95% CI, 1.2%–2.6%; n/N = 29/1600) in PsA-TT and 2.1% of subjects (95%
CI, 1.2%–3.4%; n/N = 17/800) in PsACWY; 18–29 years, 4.2% of subjects (95% CI, 3.3%–5.3%; n/N = 68/1605) in PsA-TT and 4.7% of subjects (95% CI, 3.3%–
6.4%; n/N = 37/795) in PsACWY.
b P < .0001 for the comparison of PsACWY vs PsA-TT using Cochran–Mantel–Haenszel test adjusting for age group. The difference was due to more tenderness
reported in the PsA-TT than PsACWY group.
Table 3. Summary of Subjects With Severe Adverse Events by Primary System Organ Class
Age Group, y
Vaccine
Group
Primary System Organ Class
Infections and
Infestationsa
Gastrointestinal
Disorders
Injury, Poisoning, and
Procedural Complications
Surgical and Medical
Procedures
Vascular
Disorderb All
No. No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
1–10 PsA-TT 799 6 (0.8) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 7 (0.9)
PsACWY 401 3 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.7)
11–17 PsA-TT 1600 9 (0.6) 0 (0.0) 0 (0.0) 1 (0.1) 1 (0.1) 11 (0.7)
PsACWY 800 5 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (0.6)
18–29 PsA-TT 1605 14 (0.9) 1 (0.1) 1 (0.1) 0 (0.0) 0 (0.0) 16 (1.0)
PsACWY 795 6 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (0.8)
Total PsA-TT 4004 29 (0.7) 1 (0.0) 2 (0.0) 1 (0.0) 1 (0.0) 34 (0.8)
PsACWY 1996 14 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 14 (0.7)
Abbreviations: PsACWY, group A, C, W, Y meningococcal polysaccharide vaccine; PsA-TT, group A meningococcal polysaccharide–tetanus toxoid conjugate vaccine.
a Only 2 subjects reported >1 SAE: 1 subject aged 1–10 years in the PsA-TT group and the other aged 1–10 years in the PsACWY group reported 2 SAEs that were
infections and infestations.
b One SAE that was vascular disorder (malignant hypertension) resulted in death of a subject aged 11–17 years in the PsA-TT group.
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Pregnancies
Within the study period, 4 pregnancies were reported 1–2
months after vaccination among 3 adults and 1 adolescent.
Three subjects had normal live-born deliveries 8–9 months
after vaccination, and 1 had a voluntary termination of preg-
nancy at 2 months after vaccination.
DISCUSSION
This study increased the safety database while further docu-
menting the safety speciﬁcations of PsA-TT in a randomized
controlled setting. No vaccine-related SAE occurred during
the 84-day follow-up of 4004 subjects vaccinated with a sin-
gle dose of PsA-TT, which supports that PsA-TT vaccine is
safe. Indeed, rare events are conventionally deﬁned as those
whose frequency is ≤1 per 1333 vaccinated individuals [13,
16]. Rare events could be ruled out, as no vaccine-related
SAEs were observed among the 4004 subjects vaccinated
with PsA-TT.
When compared to the licensed PsACWY vaccine, local re-
actogenicity appeared to be more frequent in the PsA-TT vac-
cine group, with a high number of instances of tenderness at the
injection site (3 times as frequent). This was also seen in previ-
ous studies [4–8] and can be explained by the presence of TT as
a carrier protein and aluminum as an adjuvant. Occurrence and
intensity of tenderness increased with the age of the vaccinated
subjects and were more frequent among adults. However, the
rates of systemic reactions, AEs, and SAEs were similar in
both vaccine groups. All AEs, whether they were serious or
not, were unrelated to the study vaccines and consisted mainly
of infection and infestations, whose distribution was consistent
with the pattern of the age-related morbidity in Mali.
In conclusion, this study conﬁrmed the excellent safety pro-
ﬁle of 1 dose of MenAfriVac when administered to its entire tar-
get population of 1–29 years of age, thus supporting the
prospects of large vaccine deployment in countries of the Afri-
can meningitis belt.
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